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Abstract Gastric cancer is traditionally divided into intestinal
and diffuse histological subtypes, but recent molecular analy-
ses have led to novel classification proposals based on geno-
mic alterations. While the intestinal- and diffuse-type tumours
are distinguishable from each other at the molecular level,
intestinal-type tumours have more diverse molecular profile.
The technology required for comprehensive molecular analy-
sis is expensive and not applicable for routine clinical diag-
nostics. In this study, we have used immunohistochemistry
and in situ hybridisation in molecular classification of gastric
adenocarcinomas with an emphasis on the intestinal subtype.
A tissue microarray consisting of 244 gastric adenocarci-
nomas was constructed, and the tumours were divided into
four subgroups based on the presence of Epstein-Barr virus,
TP53 aberrations and microsatellite instability. The intestinal-
and diffuse-type tumours were separately examined. The dis-
tribution of EGFR andHER2 gene amplifications was studied
in the intestinal-type tumours. Epstein-Barr virus positive
intestinal-type tumours were more common in male patients
(p = 0.035) and most often found in the gastric corpus
(p = 0.011). The majority of the intestinal-type tumours with
TP53 aberrations were proximally located (p = 0.010). All
tumours with microsatellite instability showed intestinal-type
histology (p = 0.017) and were associatedwith increased over-
all survival both in the univariate (p = 0.040) and multivariate
analysis (p = 0.015). In conclusion, this study shows that
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gastric adenocarcinomas can be classified into biologically
and clinically different subgroups by using a simple method
also applicable for clinical diagnostics.
Keywords Gastric cancer . Immunohistochemistry . In situ
hybridisation .Molecular classification
Introduction
Gastric cancer is one of the major causes of cancer-related
death worldwide [1]. Gastric adenocarcinomas have tradition-
ally been divided into intestinal and diffuse subtypes accord-
ing to the Laurén classification based on the histological char-
acteristics of the tumours [2]. However, The Cancer Genome
Atlas Consortium (TCGA) has recently proposed a molecular
subtyping of gastric adenocarcinomas based on the presence
of Epstein-Barr virus (EBV), microsatellite instability (MSI),
genomic stability (GS) and chromosomal instability (CIN) [3].
The majority of the GS tumours have diffuse histology, while
the other subgroups contain predominantly intestinal-type tu-
mours. An alternative classification has been proposed by the
Asian Cancer Research Group (ACRG). This proposal strat-
ifies gastric adenocarcinomas into tumours with MSI,
microsatellite-stable tumours showing epithelial to mesenchy-
mal transition (MSS/EMT), MSS tumours with intact TP53
activity (MSS/TP53+) and MSS tumours with functional loss
of TP53 (MSS/TP53−) [4]. These classification systems have
provided valuable information about the variability in biolog-
ical characteristics among gastric adenocarcinomas. Instead of
considering gastric cancer as a single disease, it has also be-
come clear that when exploring new cancer therapies, future
studies need to be conducted among defined sets of patients
whose tumours have specific genomic abnormalities. In clin-
ical practice, HER2 is the only predictive biomarker for
targeted therapy currently used for patient selection in gastric
cancer.
The complex methodologies used in these abovementioned
studies are not applicable for routine clinical diagnostics, and
some more straightforward methods have already been pro-
posed [5–8]. In this study, we have constructed a next-
generation tissue microarray (ngTMA) from 244 intestinal-
and diffuse-type adenocarcinomas of the stomach, gastro-
oesophageal junction (GOJ) and distal oesophagus [9].
Using this cohort, we have been able to identify four sub-
groups of tumours with distinct molecular and clinicopatho-
logical characteristics by combining the Laurén classification,
MSI and TP53 immunohistochemistry (IHC) and EBER in
situ hybridisation (ISH). Additionally, the analysis of E-
cadherin expression was performed in order to compare our
method with the previously published studies, and the distri-
bution of EGFR and HER2 gene amplifications were exam-
ined among these subgroups in the intestinal-type tumours.
Materials and methods
Patients and tumour specimens
The study population consists of 244 patients diagnosed with
adenocarcinoma of the stomach, GOJ or distal oesophagus at
the Turku University Hospital between years 1993 and 2012.
The initial search in the clinical database of Auria Biobank
retrieved tumour specimens from 437 patients. The exclusion
criteria were carcinoma in situ (Tis, n = 23), insufficient sam-
ple material or indeterminate histology (n = 63), neuroendo-
crine histology (n = 3) and metastatic adenocarcinoma from a
different organ (n = 6). This resulted in 190 patients with
intestinal-type tumours and 152 patients with diffuse-type tu-
mours. From these, all intestinal-type tumours and 54 repre-
sentative diffuse-type tumours were included in the ngTMA.
Among all of the patients, 11.9% (29/244) did receive preop-
erative chemotherapy (13 patients with intestinal-type and 16
with diffuse-type tumours). The type of surgery was total gas-
trectomy for 154 (63.1%) patients, subtotal gastrectomy or
tumour resection for 72 (29.5%) patients and palliative sur-
gery for 18 (7.4%) patients. The extent of surgery was deter-
mined as R0 (no residual tumour) for 180 (73.8%) patients,
R1 (microscopic residual tumour) for 34 (13.9%) patients and
R2 (macroscopic residual tumour) for 20 (8.2%) patients. The
extent of surgery could not be determined for 10 (4.1%) pa-
tients. Tumour stage was assessed according to the current
WHO Classification manual [10]. The median follow-up time
of the patients was 125months. All corresponding H&E slides
have been reviewed for confirmation of diagnosis and adequa-
cy of material. Relevant clinical information has been gath-
ered from each case. The reporting of the study has been
performed in compliance with the current recommendations
[11]. The patient characteristics are presented in Table 1.
Tissue microarray construction
The ngTMA was created as follows [9]. The appropriate
formalin-fixed paraffin-embedded (FFPE) tissue specimens
were chosen based on clinical data and retrieved from the
pathology archives. A representative haematoxylin-eosin
(H&E) section containing areas of invasive carcinoma was
selected from each tumour. New H&E slides were produced,
scanned (Pannoramic P250, 3DHistech) and uploaded into the
university digital microscopy web portal (casecenter.utu.fi).
Each slide was viewed using Pannoramic Viewer software
(3DHistech). Using the 1.0-mm annotation tool, annotations
of different colours corresponding to various histological
areas were placed onto each digital slide. Two annotations
were placed in the centre of the tumour and two annotations
in the periphery or invasive front of the tumour. The
corresponding tissue cores were then transferred into the
TMA blocks using an automated TMA instrument (TMA
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Grandmaster, 3DHistech) by overlaying each annotated
digital slide with the corresponding tissue specimen. One
tissue core containing benign tissue was selected from each
tumour to act as a control. The constructed TMA blocks were
sectioned, stained, scanned and uploaded into the web portal
(casecenter.utu.fi), and each individual spot was scored by two
pathologists (EB and NM). The resulting scores were
combined with the clinical data for statistical analysis.
The link https://seafile.utu.fi/d/7c4aa1964b/ contains
examples of our TMA results. The directory BTMA
staining^ contains low resolution images of all stainings
performed on TMA block number 7, and BTMA map and
score^ contains the map and scores of the same TMA block.
The directory BExample scoring^ contains selected high
resolution images of positive/negative and aberrant/wild-
type stained tissue cores.
Immunohistochemistry and in situ hybridisation
IHC reactions were performed on 4-μm paraffin sections of
each tumour on the TMA slides with BenchMark XT
(Ventana/Roche). For TP53, a ready-to-use antibody clone
Bp53-11 (Ventana/Roche) was used, and the protocol includ-
ed mild (30 min) CC1 pretreatment together with 28-min an-
tibody incubation. Signal detection was performed with
ultraView universal DAB Detection Kit (Ventana/Roche).
For MLH1, an antibody clone G168-15 (BD Pharmingen)
was used at 1:5 dilution together with standard (60 min)
CC1 pretreatment and 36-min antibody incubation. The signal
was detected with ultraView Universal DAB Detection Kit
and amplification kit. For MSH2, an antibody clone G219-
1129 (BD Pharmingen) was used at 1:200 dilution together
with standard CC1 pretreatment and 28-min antibody incuba-
tion. The signal was detected with ultraView Universal DAB
Detection Kit. For MSH6, an antibody clone EP49
(Epitomoc) was used at 1:200 dilution together with standard
CC1 pretreatment and 32-min antibody incubation. The signal
was detected with ultraView Universal DAB Detection Kit.
For PMS2, a ready-to-use antibody clone EPR3947 (Ventana/
Roche) was used together with extended (90 min) CC1 pre-
treatment, 44-min antibody incubation and 12-min HQ
LINKER and HRP MULTIMER enhancements. The signal
was detected with OptiView Universal DAB Detection Kit
and amplification kit. For EBV, a ready-to-use EBER (EBV-
Table 1 Patient characteristics
Number of patients All, n (%) Intestinal, n (%) Diffuse, n (%)
All 244 190 (77.9) 54 (22.1)
Median age at diagnosis (range)
72.3 (32.9–90.9) 74.4 (32.9–90.9) 66.8 (36.9–85.1)
Patient sex
Female 101 (41.4) 68 (35.8) 33 (61.1)
Male 143 (58.6) 122 (64.2) 21 (38.9)
Site of primary tumoura
Distal oesophagus 19 (7.8) 19 (10.0)
GOJ/cardia 60 (24.6) 60 (31.6)
Corpus 106 (43.4) 52 (27.4)
Antrum/pylorus 59 (24.2) 59 (31.1)
Tumour differentiation grade
Grade 1 17 (7.0) 17 (8.9) 0 (0)
Grade 2 93 (38.1) 93 (48.9) 0 (0)
Grade 3 134 (54.9) 80 (42.1) 54 (100.0)
Stage
I 46 (18.9) 40 (21.1) 6 (11.1)
II 102 (41.8) 79 (41.6) 23 (42.6)
III 83 (34.0) 61 (32.1) 22 (40.7)
IV 13 (5.3) 10 (5.3) 3 (5.6)
Follow-up status
Alive and free of disease 48 (19.7) 34 (17.9) 14 (25.9)
Alive with disease 1 (0.4) 1 (0.5) 0 (0)
Deceased 195 (79.9) 155 (81.6) 40 (74.1)
GOJ gastro-oesophageal junction
a Diffuse-type tumours are included in the tumours of the corpus
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encoded small RNA) probe (Ventana/Roche) was used togeth-
er with ISH-Protease 3 pretreatment for 28 min and 1-h probe
incubation. The signal was detected with ISH iVIEW Blue
Detection Kit. For E-cadherin, an antibody clone NCH-38
(Agilent Technologies) was used at 1:100 dilution together
with standard CC1 pretreatment and 32-min antibody incuba-
tion. The signal was detected with ultraView Universal DAB
Detection Kit and amplification kit. A complete loss of or
strong diffuse TP53 nuclear positivity was classified as aber-
rant TP53 expression. EBER ISHwas scored either positive or
negative according to the nuclear reaction. A tumour was
classified as MSI if at least one of the markers (MLH1,
MSH2, MSH6 and PMS2) showed a complete loss of nuclear
reactivity together with positive background reaction in be-
nign epithelium, smooth muscle cells and lymphocytes.
Negative nuclear reactivity with negative background was
considered controversial and not used for classification Loss
of membranous reactivity or only faint cytoplasmic reaction
was classified as aberrant E-cadherin expression (Fig. 1a). The
methods for EGFR and HER2 IHC and silver in situ
hybridisation (SISH) have been described previously
[12–15]. In short, with EGFR the scoring was based on the
most intense membranous or membranous+cytoplasmic stain-
ing (0, negative; 1+, weak; 2+, moderate; 3+, strong).
Specimens were classified as IHC high if showing 2+ or 3+
membranous or membranous+cytoplasmic staining intensity
in ≥ 10% of tumour cells. With HER2 IHC, specimens show-
ing 2+ or 3+ membranous staining in ≥ 10% of tumour cells
were classified as IHC high. The IHC high samples were
further analysed with SISH. The EGFR and HER2 IHC and
SISH were performed on whole tissue sections.
Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics
for Windows, version 21.0 (IBM Corporation, Armonk, NY).
Frequency table data were analysed using Pearson’s χ2 test or
Fisher’s exact test for categorical variables and 2 × 2 tables
were used to calculate odds ratios (OR). The Kaplan-Meier
method and log-rank test as well as Cox’s proportional haz-
ards regression model were used for univariate survival anal-
ysis. Multivariate survival analysis was performed by Cox’s
proportional hazards regression model. Recurrence-free sur-
vival (RFS) was calculated from the time of diagnosis to the
time of first recurrence, death of any cause or to the last
follow-up date. Only recurrences ≥ 6 months after the time
of diagnosis were considered relevant. Detection of a local or
distant recurrence < 6 months from the diagnosis was consid-
ered likely to present an initially advanced disease. Patients
without disease recurrence ≥ 6 months after diagnosis were
considered curatively treated. Overall survival (OS) was cal-
culated from the time of diagnosis to the time of death of any
cause or the last follow-up date. Five patients (2.0%) who had
received trastuzumab treatment for recurrent cancer were ex-
cluded from the OS analysis and additionally 13 patients with
stage IV disease (5.3%) from the RFS analysis. All statistical
tests were two-sided, and p values under 0.05 were considered
statistically significant.
Results
MSI, TP53 and E-cadherin immunohistochemistry
and EBV in situ hybridisation
EBV, MSI and TP53 were analysed in 238 tumours and E-
cadherin in 232 tumours. In the other tumours, the markers
could not be evaluated due to insufficient tissue material. EBV
RNAwas found to be present in 17/186 (9.1%) of the intesti-
nal tumours, while none of the diffuse tumours was EBV
positive (Fisher’s exact test, p = 0.028; RR 0.91, 95% CI
0.87–0.95). MSI was detected in 19/186 (10.2%) of the intes-
tinal tumours, while none of the diffuse tumours was found to
have MSI phenotype (Fisher’s exact test, p = 0.017; RR 0.90,
95% CI 0.86–0.94). Aberrant TP53 expression was observed
to be significantly more common among intestinal-type (103/
186, 55.4%) than diffuse-type tumours (10/52, 19.2%)
(Fisher’s exact test, p < 0.0001; OR 5.21, 95% CI 2.47–
11.0). Ninety-four tumours (39.5%) were found to be EBV
negative, MSS and TP53 wild-type. Of these, 52/186 (28.0%)
tumours had intestinal-type and 42/52 (80.8%) tumours had
diffuse-type histology (Fisher’s exact test, p < 0.0001; OR
0.09, 95% CI 0.04–0.20). None of the MSI tumours had both
EBV positivity and aberrant TP53 expression. Among the
intestinal-type tumours, 3/183 (1.6%) tumours had aberrant
E-cadherin expression, whereas among the diffuse-type tu-
mours, aberrant E-cadherin expression could be seen in 25/
49 (51.0%) tumours. Among the EBV negative, MSS and
TP53 wild-type tumours, 21/39 (53.8%) of the diffuse-type
tumours but none of the intestinal-type tumours (n = 51) had
aberrant E-cadherin expression.
Among the intestinal-type tumours, aberrant TP53 expres-
sion was more common in EBV negative than in EBV posi-
tive tumours (Fisher’s exact test, p < 0.0001; OR 0.041, 95%
CI 0.01–0.32). Tumours with aberrant TP53 expression were
also more frequently MSS than MSI (Fisher’s exact test,
p = 0.003; OR 5.46, 95% CI 1.74–17.2). No association was
found between aberrant E-cadherin expression and either
EBV, TP53 or MSI status. Among the diffuse-type tumours,
testing for statistical significance was not applicable for EBV
or MSI (Table 2, Fig. 1b).
EGFR and HER2 in the intestinal-type adenocarcinomas
EGFR and HER2 protein expression levels were evaluat-
ed in 183 intestinal-type adenocarcinomas. Moderate/
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strong EGFR protein expression was found in 59 (32.2%)
of the tumours and 25 (13.7%) of the tumours had
moderate/strong HER2 protein expression. Among these,
EGFR gene amplification was detected in 27/59 (14.8%
of the whole study material) tumours and HER2 gene
amplification in 24/25 (13.1% of the whole study materi-
al) tumours. No significant associations were observed
between EGFR/HER2 protein expression level or gene
amplification and TP53/EBV/MSI status. The majority of
the EGFR (n = 17) orHER2 (n = 15) gene amplifications were
found in the group of EBV negative and MSS tumours with
aberrant TP53. Most of the co-amplifications (n = 5) were also
found in this subgroup (Fig. 1b). The co-localisation of aber-
rant TP53 expression and either EGFR or HER2 gene ampli-
fication was detected more often in the proximal (distal oe-
sophagus/GOJ/cardia) than distal (corpus/antrum/pylorus)
intestinal-type tumours (Fisher’s exact test, p = 0.019; OR
2.83, 95% CI 1.21–6.61).
Fig. 1 Classification of
adenocarcinomas of the stomach,
gastro-oesophageal junction and
distal oesophagus based on
immunohistochemistry and in situ
hybridisation. a Examples of
EBER in situ hybridisation and
MLH1, TP53 and E-cadherin
immunohistochemistry in eight
oesophagogastric
adenocarcinomas. (a) EBV
positive, (b) TP53 aberration, (c)
MLH1 mutated, (d) E-cadherin
wild-type, (e) EBV negative, (f)
TP53 wild-type, (g) MLH1 wild-
type and (h) E-cadherin
aberration. b The classification of
the intestinal- and diffuse-type
adenocarcinomas of the stomach,
gastro-oesophageal junction and
distal oesophagus according to
the immunohistochemical data
and in situ hybridisation. c
Distribution of the four molecular
subtypes of intestinal-type
oesophagogastric
adenocarcinomas in different
anatomical locations.
aImmunohistochemical data
available for 238 (EBV, MSI,
TP53) or 232 tumours (E-
cadherin). bIncluding one tumour
(2%) with co-amplification EGFR
and HER2. cIncluding five
tumours (5%) with co-
amplification of EGFR and
HER2. EBV Epstein-Barr virus,
GOJ gastro-oesophageal junction,
MSS microsatellite-stable, MSI
microsatellite-instable, wt wild-
type, aberr aberration, amp
amplification
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TP53, EBVand MSI status in relation
to clinicopathological variables
Among the intestinal-type tumours, aberrant TP53 expression
was more frequent in proximal than distal tumours (Fisher’s
exact test, p = 0.002; OR 2.71, 95%CI 1.47–5.00). In contrast,
MSI phenotype was more frequent in distally located tumours
(Fisher’s exact test, p = 0.003; OR 7.10, 95% CI 1.59–31.7).
EBV positive tumours were more common among male than
female patients (Fisher’s exact test, p = 0.035; OR 4.57, 95%
CI 1.01–20.6), whereas MSI tumours were more common
among female than male patients (Fisher’s exact test,
p = 0.042; OR 2.89, 95% CI 1.07–7.36). EBV positive tu-
mours were also more often poorly differentiated than well
or moderately differentiated (Fisher’s exact test, p < 0.0001;
OR 0.08, 95% CI 0.02–0.37) and most often located in the
gastric corpus (Fisher’s exact test, p = 0.011). No significant
associations were observed between the EBV negative/MSS/
TP53 wild-type tumours and the examined clinicopathologi-
cal variables. Among diffuse-type tumours, no significant as-
sociations were found with the examined variables (Table 3).
TP53, EBVand MSI status in relation to survival
In univariate survival analysis for intestinal tumours, the pres-
ence of MSI was associated with longer overall survival (OS,
median) (124.6 versus 28.7 months, log-rank test, p = 0.040;
Cox test, p = 0.043, HR 0.54, 95% CI 0.30–0.98) but not with
recurrence-free survival (RFS). In intestinal tumours, increas-
ing depth of tumour invasion was associated with shorter RFS
and OS (RFS log-rank test, p = 0.045; Cox test, p = 0.046, HR
1.53, 95%CI 1.01–2.32; OS log-rank test, p = 0.030; Cox test,
p = 0.031, HR 1.54, 95% CI 1.04–2.28). Similarly, increasing
tumour stage was associated with shorter RFS and OS (RFS
log-rank test, p = 0.019; Cox test, p = 0.020, HR 1.56, 95% CI
1.07–2.26; OS log-rank test, p < 0.0001; Cox test p < 0.0001,
HR 1.84, 95% CI 1.32–2.57). In addition, patient age above
median at the time of diagnosis was associated with shorter
RFS and OS (RFS log-rank test, p = 0.006; Cox test,
p = 0.006, HR 1.67, 95% CI 1.16–2.42; OS log-rank test,
p = 0.026; Cox test p = 0.027, HR 1.46, 95% CI 1.04–2.03).
No significant associations were observed between TP53 or
EBV status and survival.
The multivariate model for OS included the following var-
iables: patient age at diagnosis (below versus above median,
median 72.3 years), postoperative T (T1–T2 versus T3–T4),
tumour stage (I–II versus III–IV) and MMR status (MSS ver-
sus MSI, for intestinal tumours only). Among intestinal tu-
mours, MSI status was found to be predictive for longer OS
(Cox test, p = 0.015, HR 0.46, 95% CI 0.25–0.86) while
patient age above median (Cox test, p = 0.009, HR 1.57,
95% CI 1.12–2.21) and increasing tumour stage (Cox test,
p = 0.036, HR 1.50, 95% CI 1.03–2.18) were predictive for
shorter OS. In diffuse-type tumours, patient age above median
remained as a single predictive factor for shorter OS (Cox test,
p = 0.030, HR 2.29, 95% CI 1.08–4.83) (Table 4).
Discussion
In this study, we describe a straightforward method for molec-
ular classification of gastric cancer applicable for both clinical
diagnostics and research purposes. With an emphasis on the
intestinal-type adenocarcinomas, we have used IHC and ISH
to define four subgroups of gastric adenocarcinomas with dis-
tinct molecular and clinical characteristics.
The recent molecular profiling studies have mainly been
conducted in either Western [5] or Asian populations [4, 6–8].
The TCGA study contains patients from various geographical
regions and among them they did not find any significant
difference in the prevalence of the different molecular sub-
types between the East-Asian group (Vietnam and South
Korea) and the overall group [3]. Among the intestinal-type
tumours, the frequency of EBV positive adenocarcinomas in
our Finnish study population that represents Caucasian genet-
ic background was 9.1%, which is in line with the results of
3.0–9.5% from other studies showing no clear difference be-
tween the geographical regions [3, 4, 6, 8]. The frequency of
intestinal-type MSI tumours was 10.2% in our cohort which is
similar to 9.2% found by Kim et al. (2016) but somewhat less
than 24.5–26.0% found in other studies with mixed patient
populations [3, 4]. The presence of aberrant TP53 expression
was found in 55.4% of the intestinal-type tumours in our
study. This is close to the 53.1% of the TCGA study but
somewhat different from the 31.3% found by Cristescu et al.
(2015) or 67.3% by Kim et al. (2016). Still, no clear difference
can be seen between the different geographical regions.
The molecular analyses of gastric adenocarcinomas have
shown that the intestinal- and diffuse-type tumours are distin-
guishable from each other also at the molecular level, and the
intestinal-type tumours have more diverse molecular profiles
than the diffuse-type tumours, which are the predominant sub-
type in the Bgenomically stable^ category [3, 4]. Therefore,
the intestinal-type adenocarcinomas have been the main focus
of our analyses, and a subset of diffuse-type tumours has
served as a reference group for other publications. We have
shown that the intestinal-type tumours rarely contain aberrant
E-cadherin expression; and that by beginning with the Laurén
classification, we could concentrate 25/28 (89.3%) of the tu-
mours with aberrant E-cadherin expression into the diffuse
subgroup. Notably, none of the EBV negative, MSS and
TP53 wt intestinal-type tumours showed aberrant E-cadherin
expression. This suggests that some other biomarker could be
more specific than E-cadherin in detecting the intestinal-type
tumours not characterised by EBV positivity, MSI or TP53
aberrations. In all, these observations imply that the
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histological subtype can be used as a starting point for a clin-
ically applicable method for molecular classification.
Among the diffuse-type tumours, the comparison of our
results to the other studies should be considered as suggestive
as we have analysed only a subset of the diffuse-type tumours
diagnosed during the study period. The frequency of EBV
positivity has been reported to be 3.8–9.8% among diffuse-
type tumours [3, 4, 6, 8], but in our study none of the diffuse-
type tumours was found to contain EBV positivity. Similarly,
we did not detect MSI in the diffuse-type tumours. In other
studies, the proportion of MSI diffuse-type tumours has been
reported to be relatively low (3.8–8.7%) [3, 6] with the excep-
tion of 16.9% by Cristescu et al. (2015). The frequency of
aberrant TP53 expression in our study was 19.2% among
the diffuse-type tumours, which is quite similar to the ob-
served frequencies of 26.1–27.5% [3, 4] but notably different
from 53.8% reported by Kim et al. (2016).
The subgroup of EBV negative, MSS and wild-type TP53
tumours comprised 28.0% (52/186) of the intestinal-type tu-
mours and 80.8% (42/52) of the diffuse-type tumours in our
study population. In the TCGA study, this pattern was found
in 23.0% (45/196) of the intestinal-type and 56.5% (39/69) of
the diffuse-type tumours. In the ACRG study, the respective
frequencies are 38.0% (57/150) for the intestinal-type tumours
and 45.8% (65/142) for the diffuse-type tumours.
We could demonstrate the association of EBV positivity
with male patients and the location of the tumour in the gastric
corpus as previously shown by Ahn et al. (2017).
Additionally, EBV positivity was found to be associated with
poor histological differentiation among the intestinal-type tu-
mours. Distally located tumours were more often
characterised by MSI than proximal tumours, which confirms
the results obtained by the TCGA and Cristescu et al. (2015).
We could also show thatEGFR andHER2 gene amplifications
were most common among the intestinal-type tumours with
EBV negativity, MSS and TP53 aberration, of which 17.3%
(17/98) were EGFR and 15.3% (15/98) HER2 amplified.
Notably, also among the EBV negative, MSS and TP53
wild-type tumours, the proportion of these amplifications,
15.4% (8/52) for both genes, was substantial. In the TCGA
study population, 10.6% (9/85) of the EBV negative, MSS
and TP53 aberrant tumours contained EGFR and 34.1% (29/
85) containedHER2 gene amplification. Similar to our results,
among the EBV negative, MSS and TP53 wild-type tumours,
the proportion of EGFR gene amplification was 11.1% (5/45)
and HER2 gene amplification 13.3% (6/45) [3, 16, 17]. In our
study, the co-localisation of aberrant TP53 expression together
with EGFR or HER2 gene amplification was noticed to be
more common in the proximally than distally located
intestinal-type tumours, which is in line with the results from
a recent characterisation of oesophageal carcinomas showing
strong genomic similarities between oesophageal adenocarci-
nomas and CIN-type gastric adenocarcinomas according to
the TCGA classification [18]. Additionally, we observed that
patients with MSI tumours had longer survival than patients
with MSS tumours both in the univariate and multivariate
analysis, which is consistent with earlier findings [4, 7].
Our classification method concentrated on the intestinal
subtype of gastric adenocarcinoma, where receptor tyrosine
kinase (RTK) copy number alterations are more common than
in diffuse-type tumours. In the TCGA study population, all
tumours with either EGFR or HER2 gene amplification were
observed to have intestinal-type histology [3]. However, we
also examined a subset of diffuse-type tumours in order to
make comparisons with the results obtained by other studies.
Most likely, due to this selection, we did not find EBV posi-
tivity or MSI among the diffuse-type tumours in our study
population.
In order to increase the reliability of the TMA analysis, we
have examined four tissue cores from each tumour. For the
EGFR and HER2 SISH, we have used whole slide sections in
order to account for the potential spatial heterogeneity of the
gene amplifications. Additionally, we have examined the ex-
pression of all four MSI markers instead of only one in order
to increase the reliability of the classification intoMSI orMSS
tumours. Especially in the MSI classification, there is varia-
tion in the reported prevalence of MSI phenotype, which may
partly be related to technical issues in performing and
interpreting the IHC reactions. Moreover, some variability is
inevitably related to using TP53 IHC as a surrogate marker for
TP53 gene mutations.
Our classification method differs from that suggested by
Park et al. (2016) in that our initial division was based on
the Laurén classification. After that, we continued by
categorising the tumours first by EBV and second by MSI
reactivity. Finally, we considered the presence of TP53
aberrations.
Our method was able to determine four distinct subgroups
among the intestinal-type tumours without considerable over-
lapping of the molecular markers. Among the diffuse-type
tumours in our material, EBV positivity, MSI and aberrant
TP53 expression were mutually exclusive. Among the intes-
tinal tumours, only one EBV positive tumour showed aberrant
TP53 expression and four tumours with MSI showed aberrant
TP53 expression. EBV positivity and MSI were mutually ex-
clusive also among the intestinal-type tumours, which is in
line with other studies [3, 6]. Only 3/183 intestinal-type tu-
mours (1.6%) had aberrant E-cadherin expression, and even
they could be classified as either EBV positive, MSI or TP53
aberrant. The proportion is comparable to the observed 4.1%
(8/196) of the intestinal-type tumours with E-cadherin muta-
tions in the TCGA study.
A few articles have recently been published describing dif-
ferent algorithms implementing the molecular classification
system proposed by TCGA into clinical practice [5–8].
However, only few studies have utilised the Laurén
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classification and none of them have based their proposed
algorithm on the histological subtype of the tumours. In one
study, differentially expressed genes were compared by mi-
croarray analysis between intestinal and diffuse gastric can-
cers, and a 40-gene signature was created to serve as a prog-
nostic tool [19]. As RTK amplifications are known to be
more prevalent among the intestinal-type tumours, the his-
tological subtype could be a relevant factor to take in to
account when investigating new RTK-targeting therapies
for gastric cancer [3]. In only one of these recent studies,
the evaluation of both EGFR and HER2 gene amplification
status has been performed by ISH [7]. However, the SISH
procedure was carried out on TMA slides, which potential-
ly does not account for the tumour heterogeneity. So far,
anti-EGFR antibodies have not shown survival benefit in
phase III trials including gastric or oesophagogastric can-
cer patients [20, 21]. One reason for this may be that the
screening methods used have not been able to identify the
subgroup of patients possibly responsive to anti-EGFR
treatment. In future clinical trials, the application of new
classification methods combining both histological and
molecular information may become necessary in order to
improve the clinical benefit obtained by new targeted
therapies.
In conclusion, we have demonstrated that gastric ade-
nocarcinomas can be classified into biologically and clin-
ically relevant subgroups by using a straightforward and
clinically applicable method based on the Laurén classifi-
cation together with immunohistochemistry and in situ
hybridisation.
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